undamentalytics Newsletter
Sign in

Syndax Pharmaceuticals Inc income statement

In fiscal 2025, Syndax Pharmaceuticals Inc reported revenue of $172m, up 627.8% on the year before, operating income of −$273m (a -158.4% margin) and net income of −$285m, or −$3.29 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue1122221400024172290
Research and development10324860435088118163242259273
Selling, general and administrative——————253367121180—
General and administrative121316171623——————
Operating income−21−44−62−76−58−7126−152−230−340−273−179
Interest expense—————2230−000
Income tax0000000———00
Net income−24−44−61−74−56−7325−149−209−319−285−209
Diluted EPS−$1519.27−$3.22−$2.90−$2.92−$1.84−$1.87$0.46−$2.46−$2.98−$3.72−$3.29−$2.36
Diluted shares (average)—15m21m25m30m41m54m—70m86m87m89m
EBITDA−20−44−62−76−57−7169−119−218−332−267−161

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PTGX vs SNDXSNDX vs VIRPHAT vs SNDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Syndax Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Syndax Pharmaceuticals Inc.